Table S2.

Utilities for different hypothetical possible treatment options, expressed in months of progression-free survival that patients would be willing to trade

Therapy regimen/drug administration			Possibility of side effects affecting the blooda		Possibility of side effect heart failure		Utility (expressed in months of PFS patients would be willing to trade)	Rank
Application 1b	Application 2c	Application 3d	12%	19%	2%	4%
X			X		X		14.44	1
	X		X		X		12.94	2
X				X	X		12.52	3
X			X			X	11.13	4
	X			X	X		11.02	5
	X		X			X	9.63	6
X				X		X	9.21	7
	X			X		X	7.71	8
		X	X		X		5.22	9
		X		X	X		3.31	10
		X	X			X	1.92	11
		X		X		X	0.00	12

Notes:

^aThis attribute includes thrombocytopenia, neutropenia, anemia, and hypokalemia.

^bApplication 1 describes the following therapy regimen/drug application: “oral intake once daily and once per week; physician visit once per month with a duration of approximately 2 hours; patient does not need to be accompanied.”

^cApplication 2 describes the following therapy regimen/drug application: “oral intake once daily and twice per week; physician visit once per month with a duration of approximately 2 hours; patient does not need to be accompanied.”

^dApplication 3 describes the following therapy regimen/drug application: “oral intake once daily and once per week; physician visit twice per week, including administration of one infusion per visit, with a duration per visit of ~3–4 hours; patient needs to be accompanied.” This table shows the results of the estimation of the patients’ utilities for different combinations of the three treatment-describing attributes application, side effects affecting the blood, and side effect heart failure. In the table, the negative utility associated with a shorter progression-free survival (PFS) time was translated into a “willingness to accept” this shorter time to receive a treatment with more favorable attributes regarding administration regimen and side effect profile.